SASPject PT1.2 is an antibiotic protein technology that offers a new approach to treat serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
RapidFACT will be used to screen alternative formulations designed to enhance nasal delivery, retention and efficacy of SASPject in intranasal S. aureus carriers.
Quotient MD Mark Egerton said they are looking forward to delivering an optimized drug product for the next stages of development, and helping Phico to accelerate its novel approach into patient studies.